Our experimental systems included biochemical assays in both Jurkat T cells and HEK293 cells, a genetic model of conditional Fbxo38 knockout specifically in T cells, and multiple tumor models in which FBXO38’s role was assessed in T-cell exhaustion and immunotherapy. Here, FBXO38 is linked to neoplasm.